Nvidia Invests in Doctolib: What It Means for Patients and Doctors

Nvidia is becoming a part-owner of Doctolib. The chipmaker has taken a minority stake in the French platform, which, according to the company, about 20 million patients in Germany use to book doctor’s appointments. The money matters less than the purpose: Doctolib wants to build its own AI models for medicine without depending on OpenAI or Anthropic. For patients and medical practices, that raises the question of what will change and what happens to their data.

Key takeaways

• Nvidia CEO Jensen Huang announced minority stakes in four French companies in Paris on October 13: Doctolib, Pigment, Genesis AI and Entalpic. No one disclosed amounts or stake sizes.
• According to Doctolib CEO Stanislas Niox-Chateau, Nvidia will not get a board seat. Doctolib mainly hopes for expertise and help training its own models.
• The capital is meant to speed up, among other things, a personal health assistant for patients that 400,000 people are currently testing in France.
• Doctolib says all health data, as well as its AI models, stays on servers in the EU and the UK.
• German users can control whether their health data is used for AI training under “My preferences” in their Doctolib account.

What Nvidia is buying, and why

Huang announced the stakes at a reception on Place Vendôme that was also attended by French Economy Minister Roland Lescure. Besides Doctolib, Nvidia is investing in the financial planning software company Pigment, the robotics startup Genesis AI and the materials company Entalpic, which uses AI to develop new materials for applications such as semiconductors. Paris was the first stop on a European tour that will also take Huang to London and Berlin, where Nvidia is holding its GTC developer conference next week. Huang said the company would announce, within a week, further European investments worth $2 billion, on top of the $8 billion it says it invested in Europe over the past year.

How much Nvidia is paying for the Doctolib stake is unknown. According to the French tech outlet Next, Le Figaro puts it at a few million euros. Measured against Doctolib’s last known valuation of about 3.6 billion euros, that would be a small stake. It fits Nvidia’s pattern: the company likes to invest in firms that use its technology, tying customers more closely to itself. Critics call this circular financing, because some of the money ultimately flows back into Nvidia chips. Huang rejects that, saying the stakes are small compared with the business.

For Doctolib, it is about more than capital. The company says it has been using Nvidia technology for about a year to develop its own models, and it wants access to Nvidia’s AI specialists, who are meant to support its AI team of about 100 scientists, engineers and designers. “This investment will allow us to attract AI talent faster and accelerate our development,” Niox-Chateau said, according to the German news agency dpa. Speaking to AFP, he described a sovereign AI built on Doctolib’s own models and data that does not depend on providers such as OpenAI or Anthropic.

What Doctolib plans to do with AI

In Germany, most people know Doctolib as an appointment calendar. Behind the scenes, it has long since become a software provider for medical practices. Its offerings include an AI phone assistant that takes calls for appointment booking and tools for administration and billing. In France, a consultation assistant that transcribes the doctor-patient conversation using speech recognition and turns it into draft documentation has already documented more than 12 million consultations, according to Next. Similar plans exist for Germany: the AI is supposed to produce a draft with the reason for the visit, findings and treatment, which the doctor reviews and adopts.

For patients, the main offering is the personal health assistant. It is currently being tested by 400,000 users in France and is due to be available to everyone there in 2027. According to Niox-Chateau, the Nvidia investment should significantly accelerate this work. For Germany, Doctolib has announced personalized features that are supposed to let users view past doctor visits, get prescription reminders and track their medical history digitally. It has not said when, or to what extent, these patient features will arrive there.

What happens to the data

With a US investor in a health platform, the data question is an obvious one. Doctolib stresses that all health data is stored on servers in the EU and the UK and stays there, and that the same applies to its AI models. According to Doctolib, Nvidia provides chips, computing power and open software. A minority stake without a board seat also gives the company little direct influence over the business.

Regardless of Nvidia, though, Doctolib also trains its models on user data. In France, according to Next, the company has been using data for its own AI research since the summer, and users can opt out. In Germany, new privacy terms have applied since February 2025. Under them, Doctolib relies on legitimate interest to use details such as gender and year of birth, while health data requires consent. Anyone who wants to check or withdraw that consent will find the setting under “My preferences” in their account. That is worth doing, not least because privacy advocates point out that even pseudonymized health data can, under certain circumstances, be traced back to individuals.

Analysis

The stake is small financially but revealing strategically. Nvidia no longer just sells chips; it is building a network of European application companies, and after its announced acquisition of Hugging Face, that network now extends into medicine. Doctolib, for its part, is betting on an approach that is becoming increasingly attractive for sensitive industries: its own specialized models on European servers instead of dependence on the big American language models. For medical practices, that could mean less paperwork; for patients, an assistant that knows their medical history. That is exactly why success depends less on Nvidia’s computing power than on whether Doctolib can maintain trust in how it handles health data, trust that has suffered from past privacy controversies.